PULSE BIOSCIENCES, INC. (PLSE) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, PULSE BIOSCIENCES, INC.'s filing signal turned positive.

Pulse Biosciences, Inc. is a novel ablation company developing and commercializing its proprietary Nano-pulse Stimulation (NPS) technology, a nonthermal energy modality that delivers nanosecond-duration electrical pulses to clear or kill targeted cells. The company's nPulse System, utilizing Nanosecond Pulsed-Field Ablation (nsPFA), is being explored for various medical conditions, with a primary focus on treating atrial fibrillation (AF), a market estimated at over $3 billion. Pulse Biosciences has developed the Vybrance Percutaneous Electrode System for soft tissue ablation, receiving FDA 510(k) clearance for percutaneous and intraoperative surgical procedures. Additionally, the company is advancing its cardiac surgical clamp and cardiac catheter systems for AF treatment, with the latter showing promising results in clinical studies, including a 96% procedural success rate at one year for treated patients. The company is headquartered in Miami, Florida, with operations in Hayward, California.

Revenue is primarily driven by the commercialization of the nPulse System, specifically the Vybrance Percutaneous Electrode System for soft tissue ablation, and future sales of cardiac ablation devices for atrial fibrillation.